“Brown Fat” Attracts Start-Up Interest, Highlighted At ADA 2012
Executive Summary
Bruce Spiegelman, co-founder of the start-up Ember Therapeutics and winner of ADA’s prestigious Banting Award, described how his lab at Harvard discovered the hormone irisin, which appears to be a key regulator of fat metabolism and may be responsible for beneficial functions of “brown” fat.
You may also be interested in...
Third Rock Portfolio Companies Innovate, Sometimes By Returning To The Roots Of Drug Discovery
Third Rock Ventures has raised $1.3 billion by going all-in on early stage biotech with a homegrown company strategy that requires that its own people run many of its portfolio companies after launch. It’s hard to say definitely that the strategy is working, but its investors just re-upped for a new half-billion-dollar fund.
Third Rock Ventures Rolls Its Own
Third Rock Ventures has raised $1.3 billion by going all-in on early-stage biotech with a homegrown company strategy that requires that its own people run many of its portfolio companies after launch. It’s hard to say definitively that the strategy is working, but then again, its investors just re-upped for a new half-billion-dollar fund.
Insulin The Focus At ADA 2012, But Don’t Forget GLP-1s And SGLT-2s
In anticipation of the American Diabetes Conference of 2012, analysts take a look at several categories of drugs that will be playing a major role in the future of diabetes care.